首页> 外文期刊>The Journal of Physiology >Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas
【24h】

Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas

机译:受体Mas拮抗剂完全阻断血管紧张素-(1-7)和缓激肽对小鼠微血管的血管舒张作用

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract The heptapeptide angiotensin-(1-7) is a biologically active metabolite of angiotensin II, the predominant peptide of the renin-angiotensin system. Recently, we have shown that the receptor Mas is associated with angiotensin-(1-7)-induced signalling and mediates, at least in part, the vasodilatory properties of angiotensin-(1-7). However, it remained controversial whether an additional receptor could account for angiotensin-(1-7)-induced vasorelaxation. Here, we used two different angiotensin-(1-7) antagonists, A779 and d-Pro-angiotensin-(1-7), to address this question and also to study their influence on the vasodilatation induced by bradykinin. Isolated mesenteric microvessels from both wild-type and Mas-deficient C57Bl/6 mice were precontracted with noradrenaline, and vascular reactivity to angiotensin-(1-7) and bradykinin was subsequently studied using a small-vessel myograph. Furthermore, mechanisms for Mas effects were investigated in primary human umbilical vein endothelial cells. Both angiotensin-(1-7) and bradykinin triggered a concentration-dependent vasodilatation in wild-type microvessels, which was absent in the presence of a nitric oxide synthase inhibitor. In these vessels, the pre-incubation with the Mas antagonists A779 or d-Pro-angiotensin-(1-7) totally abolished the vasodilatory capacity of both angiotensin-(1-7) and bradykinin, which was nitric oxide mediated. Accordingly, Mas-deficient microvessels lacked the capacity to relax in response to either angiotensin-(1-7) or bradykinin. Pre-incubation of human umbilical vein endothelial cells with A779 prevented bradykinin-mediated NO generation and NO synthase phosphorylation at serine 1177. The angiotensin-(1-7) antagonists A779 and d-Pro-angiotensin-(1-7) equally block Mas, which completely controls the angiotensin-(1-7)-induced vasodilatation in mesenteric microvessels. Importantly, Mas also appears to be a critical player in NO-mediated vasodilatation induced by renin-angiotensin system-independent agonists by altering phosphorylation of NO synthase.
机译:摘要七肽血管紧张素-(1-7)是血管紧张素II(肾素-血管紧张素系统的主要肽)的生物活性代谢产物。最近,我们已经表明,受体Mas与血管紧张素-(1-7)诱导的信号传导相关,并且至少部分介导血管紧张素-(1-7)的血管舒张特性。然而,是否还有其他受体可以解释血管紧张素-(1-7)-诱导的血管舒张仍存在争议。在这里,我们使用两种不同的血管紧张素-(1-7)拮抗剂A779和d-Pro-血管紧张素-(1-7)来解决这个问题,并研究它们对缓激肽诱导的血管舒张的影响。从野生型和Mas缺陷型C57Bl / 6小鼠中分离出的肠系膜微血管与去甲肾上腺素预收缩,随后使用小血管肌电图对血管紧张素-(1-7)和缓激肽的血管反应性进行研究。此外,在原代人脐静脉内皮细胞中研究了Mas效应的机制。血管紧张素-(1-7)和缓激肽都触发了野生型微血管中浓度依赖性的血管舒张,而一氧化氮合酶抑制剂不存在。在这些血管中,与Mas拮抗剂A779或d-Pro-血管紧张素-(1-7)一起预孵育完全消除了由一氧化氮介导的血管紧张素-(1-7)和缓激肽的血管舒张能力。因此,缺乏Mas的微血管缺乏响应血管紧张素-(1-7)或缓激肽的松弛能力。人脐静脉内皮细胞与A779的预孵育可防止缓激肽介导的NO生成和丝氨酸1177处的NO合酶磷酸化。血管紧张素-(1-7)拮抗剂A779和d-Pro-血管紧张素-(1-7)均能阻断Mas ,它完全控制血管紧张素-(1-7)诱导的肠系膜微血管扩张。重要的是,通过改变NO合酶的磷酸化作用,Mas似乎在由肾素-血管紧张素系统独立的激动剂诱导的NO介导的血管舒张中起关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号